NCT04421040已完成不适用
Long-term Monitoring of Patients With Cardiac Amyloidosis With Implantable Event Monitors
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Mayo Clinic
- 入组人数
- 24
- 试验地点
- 2
- 主要终点
- Sudden Death
研究概览
简要总结
Researchers are gathering information to see if using an FDA approved implantable device can help with monitoring of your heart arrhythmias.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Cardiac biopsy or technetium pyrophosphate scintigraphy confirmed patients
- •Stage I, II, and early and late stage III in numbers as described , irrespective of EF or NYHA functional class
- •Patients aged 18 -85, both genders and of all races and ethnicities.
- •Patients must be competent to give informed consent.
- •Patients must be able to have the Biomonitor 3 implanted.
- •Amyloid stage I-III patients with existing implantable cardiac devices such as pacemakers or defibrillators
排除标准
- •Significant coronary artery disease > 75% luminal stenosis in at least 1 epicardial vessel (by cardiac catheterization or coronary computed tomography), or history of myocardial infarction or coronary revascularization.
- •Congenital heart disease.
- •Pregnant patients
- •Patients whose heart failure is felt to be secondary to primary valvular disease (>moderate/severe mitral regurgitation), uncorrected thyroid disease, obstructive or hypertrophic cardiomyopathy, pericardial disease or a systemic illness.
- •Absolute contraindications to cardiac MRI (such as renal failure with GFR<30%).
- •Unwilling or unable to provide informed consent.
- •Patients with other life threatening diseases that would likely decrease their life expectancy over the next four years.
- •Patients who are post cardiac transplant.
- •Difficulty to attend the follow-up schedule due to a history of medical noncompliance, difficulty, or unwillingness to return to the study center for follow up.
- •Evidence of ongoing bacteremia or sepsis preventing implantation of a device
- •Unwilling or able to have the Biomonitor 3 interrogated
结局指标
主要结局
Sudden Death
时间窗: 6 months
Total number of patients to experience sudden death
Atrial Arrhythmias
时间窗: 6 months
Total number of participants to experience atrial arrhythmias
High Grade Atrioventricular (AV) Block
时间窗: 6 months
Total number of patients with high grade atrioventricular (AV) block.
Permanent Pacemaker Implantation
时间窗: 6 months
Total number of patients requiring permanent pacemaker implantation.
次要结局
未报告次要终点
研究者
Omar Abou Ezzeddine
Principal Investigator
Mayo Clinic
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Myocardial Injury in Patients With Cardiac Implantable Electronic Devices Undergoing Defibrillation Threshold TestingICDNCT04284800Mayo Clinic14
Unknown
2 期
Pressure Wire Guided Cardiac Resynchronisation TherapyHeart FailureNCT01464502Guy's and St Thomas' NHS Foundation Trust282
已完成
不适用
Myocardial Injury in Patients With Cardiac Implantable Electronic Devices Following Magnetic Resonance ImagingMagnetic Resonance Imaging (MRI)NCT04151953Mayo Clinic105
已完成
1 期
A Study in Healthy Adult Male Participants to Learn the Way Vericiguat is Absorbed With and Without Food When Taken as a Single Dose in Liquid Form Suitable for Children Compared to a 10 Milligram (mg) Tablet That Releases the Active Substance ImmediatelyChildrenHeart FailureNCT05086952Bayer36
已完成
不适用
Cardiac Amyloidosis Screening at Trigger Finger ReleaseTrigger FingerTransthyretin AmyloidosisPrimary Amyloidosis of Light Chain TypeAmyloidosisNCT03886155The Cleveland Clinic107